Bath & Body Works Investors Urged to Act on Legal Rights
Written by Emily J. Thompson, Senior Investment Analyst
Updated: 6 hours ago
0mins
Should l Buy BBWI?
Source: PRnewswire
- Legal Investigation: Faruqi & Faruqi LLP is investigating potential claims against Bath & Body Works, Inc. for investors who purchased or acquired securities between June 4, 2024, and November 19, 2025, indicating possible legal risks for the company.
- Investor Rights Reminder: The firm reminds investors that March 16, 2026, is the deadline to seek the role of lead plaintiff in a federal securities class action, emphasizing the importance of timely action to protect their rights.
- Market Impact: The potential legal implications may pressure Bath & Body Works' stock price, prompting investors to monitor the company's future financial performance and legal developments to assess investment risks.
- Legal Consultation Access: Investors can contact Faruqi & Faruqi partner Josh Wilson directly at 877-247-4292 or 212-983-9330 (Ext. 1310) for more information regarding their legal rights.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy BBWI?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on BBWI
Wall Street analysts forecast BBWI stock price to fall
14 Analyst Rating
4 Buy
10 Hold
0 Sell
Moderate Buy
Current: 22.430
Low
15.00
Averages
20.14
High
26.00
Current: 22.430
Low
15.00
Averages
20.14
High
26.00
About BBWI
Bath & Body Works, Inc. is a global omnichannel retailer focused on personal care and home fragrance. The Company offers a range of fragrances for the body and home, including selling collections for 3-wick candles, home fragrance diffusers, fine fragrance mists, liquid hand soaps, body lotions and body creams. It delivers customers their fragrances in multiple forms and categories. The Company sells merchandise through its retail stores in the United States and Canada, and through its Websites and other channels, under the Bath & Body Works, White Barn and other brand names. The Company’s international business is conducted through franchise, license and wholesale partners. It provides in-store experiences at more than 1,890 Company-operated Bath & Body Works locations in the United States and Canada, more than 525 international franchised locations and an online storefront at bathandbodyworks.com. Additionally, it offers a buy online pick-up in-store (BOPIS) option.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
Bath & Body Works Reports Decline in Q4 Profit
- Profit Decline: Bath & Body Works reported a fourth-quarter net profit of $403 million, or $1.99 per share, down from $453 million and $2.09 per share last year, indicating a weakening in the company's profitability.
- Adjusted Earnings: Excluding items, the company reported adjusted earnings of $415 million, or $2.05 per share, which, while slightly above expectations, still fails to offset the overall profit decline.
- Revenue Decrease: The company's fourth-quarter revenue fell to $2.724 billion, a 2.3% decrease from $2.788 billion last year, reflecting weakened market demand and increased competition.
- Future Guidance: The company provided a cautious EPS guidance range of $0.24 to $0.30 for the next quarter, indicating management's careful outlook on future performance, which may impact investor confidence.
See More
Bath & Body Works Exceeds Profit Expectations Despite Sales Decline
- Profit Beat: Bath & Body Works reported fourth-quarter adjusted EPS of $2.05, surpassing the market expectation of $1.336 billion, indicating resilience in profitability despite a 2% year-over-year sales decline.
- Divergent Sales Performance: Store sales in the U.S. and Canada fell 2.6% to $2.05 billion, while international sales rose 8.6% to $91 million, highlighting growth potential in international markets despite softness in core regions.
- Annual Performance Review: For fiscal year 2025, net sales were $7.291 billion, a slight decrease of 0.2%, with diluted EPS dropping from $3.61 to $3.11, reflecting a decline in profitability amid market challenges.
- Cautious Outlook: Bath & Body Works expects fiscal 2026 adjusted EPS between $2.40 and $2.65, below analysts' estimate of $2.80, and forecasts sales below market expectations, indicating uncertainty in future growth.
See More
Bath & Body Works Investors Urged to Act on Legal Rights
- Legal Investigation: Faruqi & Faruqi LLP is investigating potential claims against Bath & Body Works, Inc. for investors who purchased or acquired securities between June 4, 2024, and November 19, 2025, indicating possible legal risks for the company.
- Investor Rights Reminder: The firm reminds investors that March 16, 2026, is the deadline to seek the role of lead plaintiff in a federal securities class action, emphasizing the importance of timely action to protect their rights.
- Market Impact: The potential legal implications may pressure Bath & Body Works' stock price, prompting investors to monitor the company's future financial performance and legal developments to assess investment risks.
- Legal Consultation Access: Investors can contact Faruqi & Faruqi partner Josh Wilson directly at 877-247-4292 or 212-983-9330 (Ext. 1310) for more information regarding their legal rights.
See More
Bath & Body Works Reports Q4 Results Exceeding Guidance
- Q4 Sales Performance: Bath & Body Works reported net sales of $2.724 billion for Q4 2025, down 2% year-over-year, indicating increased market competition and reflecting challenges in the brand modernization process.
- Earnings Per Share: The company posted earnings per diluted share of $1.99 for Q4, down from $2.09 last year, although adjusted earnings were $2.05, demonstrating maintained profitability amid ongoing transformation efforts.
- 2026 Financial Guidance: For fiscal 2026, the company forecasts a net sales decline of 4.5% to 2.5%, with earnings per diluted share expected between $3.00 and $3.25, highlighting uncertainty in future market conditions while indicating strategic adjustments to address challenges.
- Share Repurchase Activity: In fiscal 2025, the company repurchased 15.1 million shares for $400 million, aiming to bolster shareholder confidence and enhance earnings per share despite facing sales declines.
See More
Bath & Body Works Q4 Earnings Beat Expectations
- Strong Earnings Report: Bath & Body Works reported a Q4 non-GAAP EPS of $2.05, beating expectations by $0.28, indicating robust profitability despite a 2.5% year-over-year revenue decline to $2.72 billion, which exceeded market expectations by $110 million.
- 2026 Guidance: The company forecasts a net sales decline of 4.5% to 2.5% for 2026, with earnings per diluted share expected between $3.00 and $3.25, and adjusted EPS between $2.40 and $2.65, slightly below the consensus of $2.59, reflecting uncertainty in future growth.
- Q1 Forecast: For Q1 of fiscal 2026, net sales are expected to decline between 4% to 6% compared to $1.424 billion in Q1 2025, indicating weak market demand, although EPS is projected to rise significantly to between $0.84 and $0.90 from $0.49 in the prior year.
- Stock Price Reaction: Following the earnings release, Bath & Body Works shares rose by 2.5%, reflecting investor confidence in the company's recovery plans, despite a still pessimistic near-term outlook.
See More
Bath & Body Works Reports Q4 Earnings Decline but Optimistic Outlook
- Sales Decline: Bath & Body Works reported a 2% drop in holiday quarter sales to $2.72 billion, indicating challenges in the retail environment, yet the company is focused on enhancing brand identity and market competitiveness.
- Operating Income Decrease: Operating income fell to $599 million from $678 million last year, reflecting the challenges faced during the transformation process while also demonstrating the company's commitment to future innovation.
- Cautious Future Outlook: The company anticipates a sales decline between 4.5% and 2.5%, with adjusted EPS expected to range from $2.40 to $2.65, below the $2.60 consensus, indicating multiple challenges to overcome in the short term.
- Stock Price Rebound: Despite the earnings decline, Bath & Body Works shares rose 2.7% in premarket trading to $23.03, reflecting market confidence in its transformation plan, while the short interest remains at 6.6% of the total float.
See More
Bath & Body Works Reports Decline in Q4 Profit
- Profit Decline: Bath & Body Works reported a fourth-quarter net profit of $403 million, or $1.99 per share, down from $453 million and $2.09 per share last year, indicating a weakening in the company's profitability.
- Adjusted Earnings: Excluding items, the company reported adjusted earnings of $415 million, or $2.05 per share, which, while slightly above expectations, still fails to offset the overall profit decline.
- Revenue Decrease: The company's fourth-quarter revenue fell to $2.724 billion, a 2.3% decrease from $2.788 billion last year, reflecting weakened market demand and increased competition.
- Future Guidance: The company provided a cautious EPS guidance range of $0.24 to $0.30 for the next quarter, indicating management's careful outlook on future performance, which may impact investor confidence.
See More
Bath & Body Works Exceeds Profit Expectations Despite Sales Decline
- Profit Beat: Bath & Body Works reported fourth-quarter adjusted EPS of $2.05, surpassing the market expectation of $1.336 billion, indicating resilience in profitability despite a 2% year-over-year sales decline.
- Divergent Sales Performance: Store sales in the U.S. and Canada fell 2.6% to $2.05 billion, while international sales rose 8.6% to $91 million, highlighting growth potential in international markets despite softness in core regions.
- Annual Performance Review: For fiscal year 2025, net sales were $7.291 billion, a slight decrease of 0.2%, with diluted EPS dropping from $3.61 to $3.11, reflecting a decline in profitability amid market challenges.
- Cautious Outlook: Bath & Body Works expects fiscal 2026 adjusted EPS between $2.40 and $2.65, below analysts' estimate of $2.80, and forecasts sales below market expectations, indicating uncertainty in future growth.
See More
Bath & Body Works Investors Urged to Act on Legal Rights
- Legal Investigation: Faruqi & Faruqi LLP is investigating potential claims against Bath & Body Works, Inc. for investors who purchased or acquired securities between June 4, 2024, and November 19, 2025, indicating possible legal risks for the company.
- Investor Rights Reminder: The firm reminds investors that March 16, 2026, is the deadline to seek the role of lead plaintiff in a federal securities class action, emphasizing the importance of timely action to protect their rights.
- Market Impact: The potential legal implications may pressure Bath & Body Works' stock price, prompting investors to monitor the company's future financial performance and legal developments to assess investment risks.
- Legal Consultation Access: Investors can contact Faruqi & Faruqi partner Josh Wilson directly at 877-247-4292 or 212-983-9330 (Ext. 1310) for more information regarding their legal rights.
See More
Bath & Body Works Reports Q4 Results Exceeding Guidance
- Q4 Sales Performance: Bath & Body Works reported net sales of $2.724 billion for Q4 2025, down 2% year-over-year, indicating increased market competition and reflecting challenges in the brand modernization process.
- Earnings Per Share: The company posted earnings per diluted share of $1.99 for Q4, down from $2.09 last year, although adjusted earnings were $2.05, demonstrating maintained profitability amid ongoing transformation efforts.
- 2026 Financial Guidance: For fiscal 2026, the company forecasts a net sales decline of 4.5% to 2.5%, with earnings per diluted share expected between $3.00 and $3.25, highlighting uncertainty in future market conditions while indicating strategic adjustments to address challenges.
- Share Repurchase Activity: In fiscal 2025, the company repurchased 15.1 million shares for $400 million, aiming to bolster shareholder confidence and enhance earnings per share despite facing sales declines.
See More
Bath & Body Works Q4 Earnings Beat Expectations
- Strong Earnings Report: Bath & Body Works reported a Q4 non-GAAP EPS of $2.05, beating expectations by $0.28, indicating robust profitability despite a 2.5% year-over-year revenue decline to $2.72 billion, which exceeded market expectations by $110 million.
- 2026 Guidance: The company forecasts a net sales decline of 4.5% to 2.5% for 2026, with earnings per diluted share expected between $3.00 and $3.25, and adjusted EPS between $2.40 and $2.65, slightly below the consensus of $2.59, reflecting uncertainty in future growth.
- Q1 Forecast: For Q1 of fiscal 2026, net sales are expected to decline between 4% to 6% compared to $1.424 billion in Q1 2025, indicating weak market demand, although EPS is projected to rise significantly to between $0.84 and $0.90 from $0.49 in the prior year.
- Stock Price Reaction: Following the earnings release, Bath & Body Works shares rose by 2.5%, reflecting investor confidence in the company's recovery plans, despite a still pessimistic near-term outlook.
See More
Bath & Body Works Reports Q4 Earnings Decline but Optimistic Outlook
- Sales Decline: Bath & Body Works reported a 2% drop in holiday quarter sales to $2.72 billion, indicating challenges in the retail environment, yet the company is focused on enhancing brand identity and market competitiveness.
- Operating Income Decrease: Operating income fell to $599 million from $678 million last year, reflecting the challenges faced during the transformation process while also demonstrating the company's commitment to future innovation.
- Cautious Future Outlook: The company anticipates a sales decline between 4.5% and 2.5%, with adjusted EPS expected to range from $2.40 to $2.65, below the $2.60 consensus, indicating multiple challenges to overcome in the short term.
- Stock Price Rebound: Despite the earnings decline, Bath & Body Works shares rose 2.7% in premarket trading to $23.03, reflecting market confidence in its transformation plan, while the short interest remains at 6.6% of the total float.
See More
